PhageNova Bio is at the forefront of developing innovative targeted gene expression technologies aimed at improving cancer therapies and vaccine delivery. Their proprietary platform utilizes a combination of bacteriophage and adeno-associated virus (AAV) components to create a targeted gene delivery vector, specifically designed to direct therapeutic agents to tumor cells while minimizing impact on normal tissues. This approach is exemplified by their lead asset, PNB-001, which is currently undergoing pre-clinical and IND-enabling studies for solid tumors. The technology allows for customizable targeting of various difficult-to-treat cancers, including the ability to cross the blood-brain barrier, and has demonstrated safety and efficacy in pre-clinical models.

In addition to their cancer program, PhageNova Bio is also advancing a COVID-19 vaccine initiative, PNB-V01, which employs a ligand-directed phage aerosol delivery system. This system enhances immune responses by modifying the phage genome to deliver viral protein transgenes that can induce neutralizing immune responses. The manufacturing process for their bacteriophage-based vaccines is designed to be scalable, cost-effective, and adaptable to emerging variants, with the added benefit of not requiring cold-chain storage. Overall, PhageNova Bio's technologies represent a significant advancement in targeted therapies and vaccine development, with a focus on safety, efficacy, and broad applicability.

United States

PhageNova Bio is a company that has developed a targeted gene delivery vector. The company is engaged in pioneering targeted gene expression for gene therapy.

PhageNova Bio

Company Details